Odyssey Therapeutics reports positive Phase 2a data for OD-001 in ulcerative colitis

Odyssey Therapeutics reported positive clinical proof-of-concept data for OD-001, its oral RIPK2 inhibitor, showing 27% clinical remission and 61% clinical response in moderate-to-severe ulcerative colitis patients. The company closed a $314.8M IPO and has $464M in cash expected to fund operations into late 2028, positioning it to advance late-stage development and combination trials.